Company Filing History:
Years Active: 1995-1997
Title: **Inventor Spotlight: Robert A. Smith from Seattle, WA**
Introduction
Robert A. Smith is a distinguished inventor based in Seattle, WA, who has made significant contributions to the field of biochemistry and therapeutic innovation. With a total of four patents under his name, Smith is recognized for his pioneering work in developing glucagon antagonists aimed at addressing critical health issues such as diabetes and hyperglycemia.
Latest Patents
Smith's latest patents focus on a method for inhibiting the stimulation of a glucagon-induced response. The inventions revolve around glucagon antagonists and methods related to their development and use. Notably, he has disclosed glucagon antagonists that include skyrin and its analogs, which serve to inhibit glucagon-induced pathways such as the adenylate cyclase response pathway and the inositol phosphate response pathway. His inventions can be utilized in therapeutic compositions to combat disease states associated with elevated glucose levels. Furthermore, his patents detail a biologically pure culture of ATCC accession number 74200, along with methods for producing glucagon antagonists through cultivation in a nutrient medium.
Smith's work also includes methods for detecting glucagon antagonists using recombinant DNA techniques. These methods involve expressing glucagon analogs within suitable host cells and assessing their binding effectiveness to glucagon receptors compared to native glucagon, potentially leading to the identification of new glucagon antagonists.
Career Highlights
Throughout his career, Robert A. Smith has been affiliated with Zymogenetics, Inc., a company known for its innovative biotechnological advancements. His contributions in research and patenting have positioned him as a notable figure within the organization, advancing the development of therapeutics that significantly impact public health.
Collaborations
In his pursuit of innovation, Smith collaborates closely with esteemed colleagues, including James R. Piggott and Robert R. West. These partnerships foster a collaborative environment conducive to research and development, allowing for the exchange of ideas and expertise that enhance the effectiveness of Smith's inventions.
Conclusion
Robert A. Smith's inventive work in the field of glucagon antagonists exemplifies the importance of innovation in tackling modern health challenges. His patents serve as a foundation for future research and therapeutic solutions, highlighting the vital role inventors play in advancing medical science and public health. As he continues his work at Zymogenetics, Inc., Smith is poised to make lasting contributions to the field of biochemistry and therapeutic interventions.